| Study name |
Improved Breast Cancer Therapy (I‐BCT‐1) in the Neoadjuvant and Metastatic Setting: A Phase 2 Clinical Trial Protocol Studying Biological Rationale for the Optimal Selection of Treatment Regimens |
| Methods |
Randomised, Phase 2 Clinical Trial |
| Participants |
Breast cancer patients with metastatic disease |
| Interventions |
Metastatic patients are randomised 1:1 to receive paclitaxel alone or paclitaxel in combination with carboplatin. |
| Outcomes |
OTRR. |
| Starting date |
April 2015 |
| Contact information |
Olav Engebraaten, Department of Oncology, Oslo University Hospital |
| Notes |
Would need mTNBC specific results. |
